Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-a antagonist treatment using a novel interleukin-8 reporter cell line
Project/Area Number |
15K09754
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Tohoku University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
相場 節也 東北大学, 医学系研究科, 教授 (80159269)
|
Project Period (FY) |
2015-10-21 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 乾癬 / TNF-a阻害剤 / ルシフェラーゼアッセイ / インターロイキン-8 / 薬物動態 / THP-1 / 生物学的製剤 / TNF-a阻害薬 / ルシフェラーぜアッセイ |
Outline of Final Research Achievements |
There was a significant correlation between change in PASI and inhibitory rate of TNF-a induced IL-8 promoter activity. Therapeutic monitoring of patients with psoriasis during TNF-a antagonist therapy using IL-8 reporter cell line, THP-G8 can provide a useful tool to determine objectively the efficacy of the administered TNF-a antagonists. Furthermore, using IL-2 reporter cell line, several drugs including JAK inhibitors inhibited IL-2 promoter activity.
|
Report
(4 results)
Research Products
(1 results)